Back to GetFilings.com

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

For the quarterly period ended June 30, 2003

OR

For the transition period from                          to                         

Commission File Number: 000-50082

IMPAC MEDICAL SYSTEMS, INC.

100 West Evelyn Avenue, Mountain View, California 94041

(Address of principle executive offices)

(650) 623-8800

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  x  Yes  ¨  No

Indicate by checkmark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  x  Yes  ¨  No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.    ¨

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Table of Contents

TABLE OF CONTENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995.

The statements contained in this Form 10-Q that are not purely historical are forward looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, including statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the future. Forward looking statements include statements regarding our business strategy, timing of, and plans for, the introduction of new products and enhancements, future sales, market growth and direction, competition, market share, revenue growth, operating margins and profitability. All forward looking statements included in this document are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward looking statement. Actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include our ability to expand outside the radiation oncology market or expand into international markets, lost sales or lower sales prices due to competitive pressures, ability to integrate our products successfully with related products and systems in the medical services industry, reliance on distributors and manufacturers of oncology equipment to market our products, and other factors and risks discussed in our final prospectus dated May 12, 2003 and other reports filed by us from time to time with the Securities and Exchange Commission.

i

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (unaudited)

IMPAC MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Table of Contents

IMPAC MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

Table of Contents

IMPAC MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Table of Contents

IMPAC MEDICAL SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

NOTE 1—Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of IMPAC Medical Systems, Inc. and its subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2003 are not necessarily indicative of the results that may be expected for the year ending September 30, 2003, or for any future period. The balance sheet at September 30, 2002 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These financial statements and notes should be read with the financial statements and notes thereto for the year ended September 30, 2002 included in the Company’s final prospectus dated May 12, 2003.

NOTE 2—Public Offerings

Initial Public Offering

On November 25, 2002, the Company completed an initial public offering in which it sold 1,875,000 shares of common stock at $15.00 per share for net cash proceeds of approximately $24,400,000, net of underwriting discounts, commissions and other offering costs. Upon the closing of the offering, all of the Company’s outstanding shares of redeemable convertible preferred stock automatically converted into 1,238,390 shares of common stock. In addition to the shares sold by the Company, 312,500 shares were sold by selling stockholders on the date of the offering and 328,125 shares were sold by selling stockholders in the exercise of the underwriters’ over-allotment option during December 2002.

Secondary Offering

On May 16, 2003, the Company completed a secondary offering in which it sold 200,000 shares of common stock at $19.00 per share for net cash proceeds of approximately $3,200,000, net of underwriting discounts, commissions and other offering costs. In addition to the shares sold by the Company, 2,178,223 shares were sold by selling stockholders on the date of the offering and 356,733 shares were sold by selling stockholders in the exercise of the underwriters’ over-allotment option during May 2003.

NOTE 3—Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the Company’s financial statements included in the final prospectus dated May 12, 2003. With the exception of the new significant accounting policies set forth below, the Company’s significant accounting policies have not materially changed as of June 30, 2003.

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or market. As of June 30, 2003 and September 30, 2002, inventories are comprised entirely of finished goods.

4

Table of Contents

Goodwill and other intangible assets

Goodwill and other intangible assets, including customer lists and acquired workforce, are stated at cost and were amortized on a straight-line basis over their estimated useful lives of generally two to five years. Effective October 1, 2002, the Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and Other Intangible Assets,” which establishes financial accounting and reporting for acquired goodwill and other intangible assets and supersedes Accounting Principles Board Opinion No. 17 (“APB No. 17”), “Intangible Assets.” In accordance with SFAS No. 142, the Company has ceased amortizing goodwill and instead performs an assessment for impairment at least annually by applying a fair-value based test. The Company has also reclassified the unamortized balance of acquired workforce to goodwill. Accordingly, no goodwill or acquired or acquired workforce amortization was recognized during the three and nine months ended June 30, 2003. The provisions of SFAS No. 142 also required the completion of a transitional impairment test within 12 months of adoption, with any impairment treated as a cumulative effect of change in accounting principle. During the first quarter of fiscal 2003, the Company completed the transitional impairment test, which did not result in any impairment of recorded goodwill.

For comparative purposes, the following table illustrates the Company’s net income (loss) available for common stockholders adjusted to exclude goodwill and acquired workforce amortization expense as if amortization had ceased October 1, 2001 (in thousands, except per share data):

Redeemable convertible preferred stock

Upon the closing of the Company’s initial public offering in November 2002, all outstanding shares of redeemable convertible preferred stock automatically converted into an equal number of shares of common stock. Prior to the initial public offering, the carrying value of the redeemable convertible preferred stock was increased by periodic accretions using the effective interest method, so that the carrying amount would equal the redemption value at the redemption date. These increases were effected through charges against retained earnings.

5

Table of Contents

Accounting for stock-based compensation

In December 2002, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure—an amendment of FASB Statement No. 123” (“SFAS No. 148”) which amends FASB Statement No. 123, “Accounting for Stock-Based Compensation” (“SFAS No. 123”), to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The transition and annual disclosure requirements of SFAS No. 148 are effective for fiscal years ending after December 15, 2002. The interim disclosure requirements are effective for interim periods ending after December 15, 2002.

The Company uses the intrinsic value method of APB Opinion No. 25 (“APB No. 25”), “Accounting for Stock Issued to Employees,” in accounting for its employee stock options, and presents disclosure of pro forma information required under SFAS No. 123, as amended by SFAS No. 148. No compensation expense is included in the net income available for common stockholders as reported during the three and nine months ended June 30, 2003. During the three and nine months ended June 30, 2002, a total of $50,000 in compensation expense relating to options granted to members of the Board of Directors is included in the net loss available for common stockholders.

Had compensation costs been determined based upon the fair value at the grant date, consistent with the methodology prescribed under SFAS No. 123, the Company’s total stock-based compensation cost, pro forma net income (loss) available for common stockholders and pro forma net income (loss) per common share, basic and diluted, would have been as follows (in thousands, except per share data):

The determination of fair value of all options granted after the Company’s initial public offering include an expected volatility factor in addition to the risk free interest rate, expected term and expected dividends.

6

Table of Contents

Other comprehensive loss

Comprehensive loss generally represents all changes in stockholders’ equity except those resulting from investments or contributions by stockholders. The Company’s unrealized gains and losses on available-for-sale securities and cumulative translation adjustments represent the components of comprehensive loss that were excluded from the net income (loss) available for common stockholders. Total comprehensive income (loss) for the three and nine months ended June 30, 2003 and June 30, 2002, is presented in the following table (in thousands):

Net income (loss) per common share

Basic net income (loss) per common share is computed by dividing net income (loss) available for common stockholders by the weighted-average number of vested common shares outstanding for the period. Diluted net income (loss) per common share is computed giving effect to all potential dilutive common stock, including options and redeemable convertible preferred stock.

A reconciliation of the numerator and denominator used in the basic and diluted net income (loss) per share follows (in thousands).

The following outstanding options and redeemable convertible preferred stock were excluded from the computation of diluted net income (loss) per share as their effect is antidilutive (in thousands):

7

Table of Contents

Recent accounting pronouncements

In November 2002, the FASB issued FASB Interpretation No. 45 (“FIN 45”), “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” FIN 45 requires that upon issuance of a guarantee, a guarantor must recognize a liability for the fair value of an obligation assumed under a guarantee. FIN 45 also requires additional disclosures by a guarantor in its interim and annual financial statements about the obligations associated with guarantees issued. The recognition provisions of FIN 45 are effective for any guarantees issued or modified after December 31, 2002. These consolidated financial statements comply with the disclosure requirements of this interpretation.

In November 2002, the Emerging Issues Task Force (“EITF”) reached a consensus on Issue No. 00-21, “Revenue Arrangements with Multiple Deliverables.” EITF Issue No. 00-21 provides guidance on how to account for arrangements that involve the delivery or performance of multiple products, services and/or rights to use assets. The provisions of EITF Issue No. 00-21 will apply to revenue arrangements entered into in fiscal periods beginning after June 15, 2003. As the Company accounts for multiple element arrangements under the higher-level authoritative literature of Statement of Position No. 97-2, “Software Revenue Recognition,” as amended, the Company expects that the adoption of EITF Issue No. 00-21 will have no material impact on its financial position or on its results of operations.

In January 2003, the FASB issued FASB Interpretation No. 46 (“FIN 46”), “Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51.” FIN 46 requires certain variable interest entities to be consolidated by the primary beneficiary of the entity if the equity investors in the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. FIN 46 is effective immediately for all new variable interest entities created or acquired after January 31, 2003. For variable interest entities created or acquired prior to February 1, 2003, the provisions of FIN 46 must be applied for the first interim or annual period beginning after June 15, 2003. The Company expects that the adoption of FIN 46 will have no material impact on its financial position or on its results of operations.

In May 2003, the FASB issued Statement of Financial Accounting Standards No. 150, “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity” (“SFAS No. 150”). SFAS No. 150 establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances). SFAS No. 150 is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The Company expects that the adoption of SFAS No. 150 will have no material impact on its financial position or on its results of operations.

NOTE 4—Commitments

Facilities

In December 2002, the Company entered into a sublease agreement to lease additional office space in Cambridge, Massachusetts. The sublease expires April 4, 2006. Total obligations under the sublease amount to $1,077,180 or $359,060 per year, payable in equal monthly installments.

In February 2003, the Company executed an addendum to the existing facility lease to expand its corporate headquarters facility. The addendum terminates concurrently with the original lease in March 2007. Total obligations under the addendum amount to $1,717,307, or $431,424 per year, payable in equal monthly installments.

NOTE 5—Common Stock Subject to Rescission Rights

Prior to the effectiveness of the Company’s registration statement for its initial public offering, an officer of the Company sent an email to 15 friends whom he had designated as potential purchasers of common stock in a directed share program in connection with the initial public offering. The email requested that the recipients send an indication of interest to the officer. The email was not accompanied by a preliminary prospectus and may have constituted a prospectus that does not meet the requirements of the Securities Act of 1933. The email was promptly followed by telephone conversations advising recipients that they could indicate an interest in purchasing shares

8

Table of Contents

only after they had received a preliminary prospectus. If the email did constitute a violation of the Securities Act of 1933, the recipients of the letter who purchased common stock in the Company’s initial public offering could have the right, for a period of one year from the date of their purchase of common stock, to obtain recovery of the consideration paid in connection with their purchase of common stock or, if they had already sold the stock, sue the Company for damages resulting from their purchase of common stock. As of June 30, 2003, the Company has classified a total of 6,500 shares of common stock which have these rescission rights outside of stockholders’ equity, as the redemption features are not within the control of the Company.

NOTE 6—Stockholders’ Equity

Reincorporation

On October 29, 2002, the Company’s Board of Directors and stockholders approved the reincorporation of the Company in the state of Delaware, which became effective on November 13, 2002. Under the terms of its Certificate of Incorporation, the Company is authorized to issue 60,000,000 shares of $0.001 par value common stock and 5,000,000 shares of $0.001 par value preferred stock. The Board of Directors has the authority to issue the undesignated preferred stock in one or more series and to fix the rights preferences, privileges and restrictions thereof. The accompanying condensed consolidated financial statements have been retroactively restated to give effect to the reincorporation.

9

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the related notes appearing in our final prospectus dated May 12, 2003. Our discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth elsewhere in this Form 10-Q and our final prospectus dated May 12, 2003.

Overview

We provide information technology systems for cancer care. Our systems provide electronic medical record, imaging, decision support, scheduling and billing applications in an integrated platform to manage the complexities of cancer care, from detection and diagnosis through treatment and follow-up. We were founded in 1990, and our growth has been primarily organic, supplemented by several product and small company acquisitions.

Net Sales and Revenue Recognition

We sell our products directly throughout the world and primarily in North America, Europe and the Pacific Rim countries. In addition, we use non-exclusive distributors to augment our direct sales efforts. Sales through distributors represented 6.8% and 6.5% of our total net sales in the three and nine months ended June 30, 2003, respectively, 10.0% and 11.4%, for the same periods in fiscal 2002, respectively, all of which were sold through Siemens Medical Systems, Inc. The decline in distributor sales as a percentage of net sales is primarily attributable to a higher growth rate in our direct sales. We have signed agreements with other distributors, which have not yet generated sales. Revenues from the sale of our products and services outside the United States accounted for 4.8% and 6.4% of our net sales in the three and nine months ended June 30, 2003, respectively, and 4.8% and 5.0% of our net sales for the same periods in fiscal 2002, respectively. The decline in international sales as a percentage of net sales is primarily attributable to a higher growth rate in our domestic sales.

We license point-of-care and registry software products. Our point-of-care products are comprised of modules that process administrative, clinical, imaging and therapy delivery information. Our registry products aggregate data on patient outcomes for regulatory and corporate reporting purposes. Currently, a majority of our point-of-care software is licensed on a perpetual basis, and a majority of our registry sales is licensed on a term basis.

Our focus with regard to software licensing and maintenance and support service is to provide flexibility in the structure and pricing of our product offerings to meet the unique functional and financial needs of our customers. For those customers who license on a perpetual basis, we promote annual maintenance and support service agreements as an incremental investment designed to preserve the value of the customer’s initial investment. For those customers who license on a term basis, annual maintenance and support contributes greatly to the value of the annual license, and the two cannot be segregated from each other. For those customers using our application service provider option, independent of the licensing method, these annual fees allow the customer to outsource, in a cost effective manner, support and connectivity functions that are normally handled by internal resources.

The decision to implement, replace, expand or substantially modify an information system is a significant commitment for healthcare organizations. In addition, our systems typically require significant capital expenditures by the customer. Consequently, we experience long sales and implementation cycles. The sales cycle for our systems ranges from six to 24 months or more from initial contact to contract execution. Our implementation cycle generally ranges from three to nine months from contract execution to completion of implementation.

We record orders for products licensed on a perpetual basis upon the receipt of a signed purchase and license agreement, purchase order, and a substantial deposit. We record orders for products licensed on a term basis upon receipt of a signed purchase and license agreement, purchase order and a deposit typically equal to the first year’s fees. All contract deposits are held as a liability until the customer has accepted the product as outlined in the terms and conditions set forth in the purchase and license agreement. Maintenance and support is recorded as deferred revenue upon the invoice date and held as a current liability on the balance sheet. Under the terms of the original purchase and license agreement, maintenance and support automatically renews on an annual basis unless the customer provides a written cancellation. We recognize revenue from these sales ratably over the underlying maintenance period.

10

Table of Contents

For direct software sales licensed on a perpetual basis, we include one year of maintenance and support as part of the purchase price. We recognize revenue upon acceptance of the installed product at the customer site. Since the first year of maintenance and support is included in the purchase price, we defer 12% of the purchase price and recognize that portion of the revenue ratably over a twelve-month period. Standard annual fees for maintenance and support after the first year equal 12% of the then current list price unless the customer negotiates other terms or service levels. We recognize these fees ratably over the applicable twelve-month period.

For direct software sales licensed on a term basis, the initial term lasts from three to five years with annual renewals after the initial term. The customer pays a deposit typically equal to the initial annual fee upon signing the license agreement, and we invoice the customer for subsequent annual fees 60 days before the anniversary date of the signed agreement. We recognize revenue for the annual fees under these term license agreements ratably over the applicable twelve-month period. The purchase price includes annual maintenance and support.

We recognize revenue from third-party products and related configuration and installation services sold with our licensed software upon acceptance by the customer. We recognize revenue from third-party products sold separately from our licensed software upon delivery. Third-party products represented 4.5% and 4.1% of our total net sales in the three and nine months ended June 30, 2003, respectively, and 5.0% and 4.1% for the same period in fiscal 2002, respectively. The decrease in third-party sales as a percentage of net sales is attributable to a higher growth rate in our net sales relative to third-party product sales.

We recognize distributor related revenues upon the receipt of a completed purchase order and the related customer information needed to generate software registration keys, which allow us to distribute the software to the end user and satisfy our regulatory information tracking requirements. We invoice maintenance and support annually and recognize revenue ratably over the applicable twelve-month period.

Costs and Expenses

A large part of our company cost structure is driven by the number of employees and all related benefit and facility costs. As a result, a significant amount of strategic and fiscal planning is focused on this area, so we can develop internal resources at a controlled and sustainable rate. Since revenue recognition happens subsequent to all implementation and training activities, we incur the costs of labor, travel and some third-party product expenses in advance.

Cost of sales consists primarily of:

System installations require several phases of implementation in the process of accepting product delivery and have led to our development of a highly specialized client service organization. All new orders require multiple site visits from our personnel to properly install, configure and train customer personnel. Several point-of-care products are used with various third-party hardware and software products that are also sold and configured during the implementation process. After the initial implementation process, our application support staff provides phone support and any applicable system updates. A substantial percentage of engineering costs are allocated to client services due to continuing engineering efforts related to the support and enhancement of our products. Historically, cost of sales has increased at approximately the same rate as net sales. However, as newly developed products and acquired product lines are released to the customers, additional investments in client service staff could cause gross margins to fluctuate.

11

Table of Contents

Research and development expenses include costs associated with the design, development and testing of our products. These costs consist primarily of:

We currently expense all research and development costs as incurred. Our research and development efforts are periodically subject to significant non-recurring costs that can cause fluctuations in our quarterly research and development expense trends. We expect that research and development expenses will increase in absolute dollars for the foreseeable future as we continue to invest in product development.

Sales and marketing expenses primarily consist of:

We have recently expanded our sales force, made significant investments in marketing communications and increased trade show activities to enhance market awareness of our products. We expect that sales and marketing expenses will increase in absolute dollars for the foreseeable future as we continue to expand our sales and marketing capabilities.

General and administrative expenses primarily consist of:

A significant portion of facility, infrastructure and maintenance costs are allocated as overhead to other functions based on distribution of headcount. Our general and administrative expenses increased after our initial public offering, and we expect these expenses will remain higher in absolute dollars in the future.

Depreciation and Amortization

Our property and equipment is recorded at our cost minus accumulated depreciation and amortization. We depreciate the costs of our tangible capital assets on a straight-line basis over the estimated economic life of the asset, which is generally three to seven years. Acquisition related intangible assets have historically been amortized based upon the estimated economic life, which is generally two to five years. Leasehold improvements and equipment purchased through a capital lease are amortized over the life of the related asset or the lease term, if shorter. If we sell or retire an asset, the cost and accumulated depreciation is removed from the balance sheet and the appropriate gain or loss is recorded. We expense repair and maintenance costs as incurred.

12

Table of Contents

Accretion of Redeemable Convertible Preferred Stock

From September 27, 2002 until our initial public offering, the holders of a majority of our then outstanding redeemable convertible preferred stock could have required us to redeem the preferred shares by paying in cash an amount equal to the greater of $3.23 per share or the fair market value plus all declared or accumulated but unpaid dividends within thirty days. These shares automatically converted to common stock upon the closing of our initial public offering in November 2002. We accreted charges that reflected the increase in market value of the redeemable convertible preferred stock as an adjustment to retained earnings and, as a result, increased the amount of net loss attributable to common stockholders. After the initial public offering, no further accretion has been required. The redemption value of the redeemable convertible preferred stock was $16.7 million at the time of the initial public offering. This amount was reclassified on our balance sheet from redeemable convertible preferred stock to common stock and additional paid-in capital upon the closing of the initial public offering.

Results of Operations

The following table sets forth certain operating data as a percentage of net sales for the periods indicated:

Comparison of Three Months Ended June 30, 2003 and 2002

Net Sales. Net sales increased 34.1% to $16.3 million in the three months ended June 30, 2003 from $12.2 million for the same period in 2002. Net software related sales increased 35.8% to $11.4 million in the three months ended June 30, 2003 from $8.4 million for the same period in 2002. Sales of imaging systems accounted for $1.3 million of the $3.0 million increase, sales of additional new products in oncology accounted for $676,000, with the remaining increase primarily due to new sales in registry and laboratory software. An increase in the average system price, due primarily to an increase in the number of products included in each order, contributed 46.6% of the overall increase in net software related sales in the three months ended June 30, 2003 as compared to the same period in 2002, with the remaining contribution attributable to an increase in the volume of installations.

13

Table of Contents

Maintenance and services increased 30.2% to $4.9 million for the three months ended June 30, 2003 from $3.7 million for the same period in 2002. Maintenance and support contracts contributed primarily to the $1.2 million increase. Our continued high customer retention on maintenance and support contracts, the general price increase, and expansion of our service offerings all contributed to the growth of maintenance and services in absolute dollars. The associated decrease in maintenance and services as a percentage of total net sales is attributable to the higher growth rate in net software sales.

Cost of Sales. Total cost of sales increased 52.0% to $4.8 million for the three months ended June 30, 2003 from $3.2 million for the same period in fiscal 2002. Our gross margin decreased to 70.6% for the three months ended June 30, 2003 from 74.1% for the same period in fiscal 2002. Cost of sales relating to net software sales increased 42.0% to $2.9 million for the three months ended June 30, 2003 from $2.0 million for the same period in fiscal 2002. Our gross margin associated with net software sales decreased to 74.9% for the three months ended June 30, 2003 compared to 76.0% for the same period in fiscal 2002. The increase in expenses related to $502,000 in employee costs, $219,000 in third party license fees, $136,000 in travel expenses and $7,000 in implementation costs offset by a $14,000 reduction in telephone costs. Cost of sales relating to maintenance and services increased 70.1% to $1.9 million for the three months ended June 30, 2003 from $1.1 million for the same period in fiscal 2002. Our gross margin associated with maintenance and services decreased to 60.6% for the three months ended June 30, 2003 from 69.9% for the same period in fiscal 2002. The increase in expenses of $791,000 was related to $411,000 in employee related expenses, $207,000 in continuing engineering costs, $116,000 in telecommunication costs associated with our data center operations, $44,000 in travel expenses and $14,000 in supplies. Planned investment in our support organization to accommodate the application service provider agreement signed with US Oncology and continued development of our direct international support presence for the three months ended June 30, 2003 contributed to the decline in our gross margin associated with maintenance and services.

Research and Development. Research and development expenses increased 37.2% to $2.6 million for the three months ended June 30, 2003 from $1.9 million for the same period in fiscal 2002. As a percentage of total net sales, research and development expenses increased to 16.1% for the three months ended June 30, 2003 from 15.7% for the same period in fiscal 2002. Additional engineering headcount and the associated personnel expenses were the primary factors for the increase in absolute dollars. The increase as a percentage of total net sales in the three months ended June 30, 2003 was due to increased research and development expenses relative to net sales.

Sales and Marketing. Sales and marketing expenses increased 22.9% to $3.8 million for the three months ended June 30, 2003 from $3.1 million for the same period in fiscal 2002. As a percentage of total net sales, sales and marketing expenses decreased to 23.0% for the three months ended June 30, 2003 from 25.2% for the same period in fiscal 2002. The increase in expenses related to $389,000 in employee related costs, $204,000 in travel expenses, $155,000 in commission expense, $17,000 in advertising expense, offset by a reduction of $34,000 in supplies, $17,000 in outside services for marketing communications and $10,000 in trade show costs. The decrease as a percentage of total net sales in the three months ended June 30, 2003 was due to increased net sales relative to sales and marketing expenses.

General and Administrative. General and administrative expenses increased 13.7% to $1.4 million for the three months ended June 30, 2003 from $1.2 million for the same period in fiscal 2002. As a percentage of total net sales, general and administrative expenses decreased to 8.6% for the three months ended June 30, 2003 from 10.1% for the same period in fiscal 2002. The increase in absolute dollars was primarily due to increases of $131,000 in employee related expenses, $109,000 in outside professional service fees, $85,000 in rent expense, $42,000 in business insurance, $29,000 in maintenance fees and an $18,000 in depreciation expense offset by decreases in bad debt expense of $226,000, telephone expenses of $14,000, travel expenses of $4,000 and regulatory fees of $3,000. The decrease in the bad debt expense is due to increased collection efforts during the three months ended June 30, 2003.

Write-off of Purchased In-Process Research and Development. In April 2002, we acquired Intellidata, Inc. At the time of acquisition, the purchased in-process technology was not considered to have reached technological feasibility and it had no alternative future use. Accordingly, $116,000 of acquired in-process research and development was recorded as a component of operating expense during the three months ended June 30, 2002.

Amortization of Intangible Assets. Amortization expense decreased 56.5% to $70,000 for the three months ended June 30, 2003 from $161,000 for the same period in fiscal 2002. Amortization expense was higher in the prior year period primarily due to the adoption of Statement of Financial Accounting Standards No. 142 “Goodwill and other Intangible Assets.” Effective October 1, 2002, we have ceased amortization of goodwill and acquired workforce and this, along with the expiration of the useful lives of previously acquired intangible assets has contributed to an overall decline in total amortization expense for the three month period.

14

Table of Contents

Operating Income. Operating income increased 44.4% to $3.7 million for the three months ended June 30, 2003 from $2.5 million for the same period in fiscal 2002. Operating income increased significantly due to the higher rate of increase in net sales relative to the rate of increase in operating expenses.

Interest and Other Income, Net. Interest and other income, net increased 36.4% to $146,000 for the three months ended June 30, 2003 from $107,000 for the same period in fiscal 2002. The increase is primarily related to additional interest earned on our public offering proceeds.

Income Taxes. Our effective tax rate was 37.0% for the three months ended June 30, 2003 and 2002. The increase in absolute dollars was due to higher operating income.

Accretion of Redeemable Convertible Preferred Stock. Historically, each reporting period, the carrying value of the redeemable convertible preferred stock has been increased by periodic accretions, using the effective interest method, so that the carrying amount would equal the redemption value at the redemption date. These increases were effected through charges against retained earnings. Several factors influenced our determination of the value of the redeemable convertible preferred stock. These factors included plans for the initial public offering, the performance of our business, changes in our business model and significant product introductions, current market conditions and the performance of the stock price of our comparable companies. During the three months ended June 30, 2002, we recorded accretion charges of $3.3 million, representing the increase in the redemption value of the Series A redeemable convertible preferred stock. Upon the closing of our initial public offering in November 2002, all shares of our redeemable convertible preferred stock automatically converted into an equal number of shares of common stock. Therefore, we did not incur accretion charges related to the Series A redeemable convertible preferred stock during the three months ended March 31, 2003 and June 30, 2003.

Comparison of Nine Months Ended June 30, 2003 and 2002

Net Sales. Net sales increased 34.5% to $43.9 million in the nine months ended June 30, 2003 from $32.6 million for the same period in 2002. Net software related sales increased 34.8% to $29.9 million in the nine months ended June 30, 2003 from $22.2 million for the same period in 2002. Sales of imaging systems accounted for $2.9 million of the $7.7 million increase, new system sales in oncology accounted for $2.5 million, sales of additional new products in oncology accounted for $2.0 million, and the remaining increase attributed to new sales in registry, urology and laboratory software. An increase in the average system price, due primarily to an increase in the number of products included in each order, contributed 41.7% of the overall increase in net software related sales in the nine months ended June 30, 2003 as compared to the same period in 2002, with the remaining contribution attributable to an increase in volume of installations. Maintenance and services also increased 33.9% to $13.9 million for the nine months ended June 30, 2003 from $10.4 million for the same period in 2002. Maintenance and support contracts contributed $3.4 million of the $3.5 million increase and additional training and installation contributed $171,000. Our continued high customer retention on maintenance and support contracts, the general price increase, and expansion of our service offerings all contributed to the growth of maintenance and services in absolute dollars. The associated decrease in maintenance and services as a percentage of total net sales is attributable to the higher growth rate in net software sales.

Cost of Sales. Total cost of sales increased 46.8% to $12.7 million for the nine months ended June 30, 2003 from $8.7 million for the same period in fiscal 2002. Our gross margin decreased to 70.9% for the nine months ended June 30, 2003 from 73.4% for the same period in fiscal 2002. Cost of sales relating to net software sales increased 29.4% to $7.5 million for the nine months ended June 30, 2003 from $5.8 million for the same period in fiscal 2003. Our gross margin associated with net software sales increased to 75.1% for the nine months ended June 30, 2003 from 74.0% for the same period in fiscal 2002. The increase in expenses related to $755,000 in employee related costs, $482,000 in supplies and materials, $242,000 in travel expenses and $19,000 in telephone expense offset by a $9,000 reduction in implementation expenses. The improvement in gross margins associated with net software sales relates to stronger demand for implementation of new systems during the nine months ended June 30, 2003 as well as efficiencies gained by organizational investments during fiscal 2002. Cost of sales relating to maintenance and services increased 80.9% to $5.3 million for the nine months ended June 30, 2003 from $2.9 million for the same period in fiscal 2002. Our gross margin associated with maintenance and services decreased to 62.0% for the nine months ended June 30, 2003 from 71.9% for the same period in fiscal 2002. The increase in expenses was associated with $1.1 million in employee related expenses, $557,000 in continuing engineering costs, $517,000 in telecommunication costs, $153,000 in travel expenses, and $57,000 in supplies. Planned investment in our support organization to accommodate the application service provider agreement signed with US Oncology and

15

Table of Contents

continued development of our direct international support presence for the nine months ended June 30, 2003 contributed to the decline in our gross margin associated with maintenance and services.

Research and Development. Research and development expenses increased 25.6% to $7.1 million for the nine months ended June 30, 2003 from $5.6 million for the same period in fiscal 2002. As a percentage of total net sales, research and development expenses decreased to 16.2% for the nine months ended June 30, 2003 from 17.3% for the same period in fiscal 2002. Additional engineering headcount and the associated personnel expenses were the primary factors for the increase in absolute dollars. The decrease as a percentage of total net sales in the nine months ended June 30, 2003 was due to increased net sales relative to research and development expenses.

Sales and Marketing. Sales and marketing expenses increased 15.1% to $10.4 million for the nine months ended June 30, 2003 from $9.0 million for the same period in fiscal 2002. As a percentage of total net sales, sales and marketing expenses decreased to 23.5% for the nine months ended June 30, 2003 from 27.6% for the same period in fiscal 2002. The increase in expenses related to $661,000 in employee related costs, $448,000 in travel expenses, $437,000 in commissions due to higher sales, $15,000 in advertising expenses, $10,000 in telephone costs and $4,000 in trade show expenses offset by reductions of $131,000 in outside services for marketing communications, $44,000 in sponsorships and $38,000 in supplies. The decrease as a percentage of total net sales in the nine months ended June 30, 2003 was due to increased net sales relative to sales and marketing expenses.

General and Administrative. General and administrative expenses increased 28.5% to $4.1 million for the nine months ended June 30, 2003 from $3.2 million for the same period in fiscal 2002. As a percentage of total net sales, general and administrative expenses decreased to 9.3% for the nine months ended June 30, 2003 from 9.6% for the same period in fiscal 2002. The increase in absolute dollars was primarily due to increases in business insurance premiums of $265,000, employee related expenses of $245,000, rent expense of $135,000, professional service fees of $109,000, outside services of $103,000, travel expenses of $54,000, depreciation expense of $54,000, maintenance expenses of $27,000 and regulatory fees of $24,000 offset by reductions of $40,000 in bad debt expense, $39,000 in telephone expense, $20,000 in charitable contributions and $20,000 in supplies. The decrease in the bad debt expense is due to recent increases in our accounts receivable collection efforts.

Write-off of Purchased In-Process Research and Development. In April 2002, we acquired Intellidata, Inc. At the time of acquisition, the purchased in-process technology was not considered to have reached technological feasibility and it had no alternative future use. Accordingly, $116,000 of acquired in-process research and development was recorded as a component of operating expense during the nine months ended June 30, 2002.

Amortization of Intangible Assets. Amortization expense decreased 28.0% to $275,000 for the nine months ended June 30, 2003 from $382,000 for the same period in fiscal 2002. Amortization expense was higher in the prior year period primarily due to the adoption of Statement of Financial Accounting Standards No. 142. Effective October 1, 2002, we have ceased amortization of goodwill and acquired workforce and this, along with the expiration of the useful lives of previously acquired intangible assets has contributed to an overall decline in total amortization expense for the nine month period.

Operating Income. Operating income increased 65.9% to $9.3 million for the nine months ended June 30, 2003 from $5.6 million for the same period in fiscal 2002. Operating income increased significantly due to the higher rate of increase in net sales relative to the rate of increase in operating expenses.

Interest and Other Income, Net. Interest and other income, net increased 21.5% to $361,000 for the nine months ended June 30, 2003 from $297,000 for the same period in fiscal 2002. The increase is primarily related to interest earned on our additional cash balances invested from our public offering proceeds, offset by lower interest income from investments in short and long-term marketable securities resulting from lower interest rates in the 2003 period.

Income Taxes. Our effective tax rate was 37.0% for the nine months ended June 30, 2003 and 2002. The increase in absolute dollars was due to higher operating income.

Accretion of Redeemable Convertible Preferred Stock. During the nine months ended June 30, 2003, we recorded accretion charges of $2.2 million, all of which was incurred during the first quarter in the time period leading up to the initial public offering. This represents a 73.0% decrease from the accretion charges incurred in the nine months ended June 30, 2002 of $8.2 million. Upon the closing of our initial public offering in November 2002, all shares of our redeemable convertible preferred stock automatically converted into an equal number of shares of common stock. Therefore, we have not incurred, nor will we incur, accretion charges related to the Series A redeemable convertible preferred stock after our initial public offering.

16

Table of Contents

Backlog